Basic demographic information was obtained from the registered persons database, a registry containing a single, unique record for all ontario residents ever issued a health card.
M.A. Krieg, MD, PD Internal Medicine, University Hospital, Lausanne; D. Hans, Ph.D, PD, MBA, Nuclear Medicine, Geneva University Hospital; J. Cornuz, MD, PD, Internal Medicine, University Hospital, Lausanne; C. Ruffieux, Msc, A.M. Schott, MD, Medical Information, Hospices Civils of Lyon, Lyon, France; Prof P. J. Meunier, MD, Inserm u 403, Edouard Herriot Hospital, Lyon, France.; Prof P. Burckhardt, MD, Internal Medicine, University Hospital, Lausanne, Switzerland; and the SEMOF and EPIDOS study groups.
Author Affiliations: Division on Substance Abuse, New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University Drs Collins and Kleber and Ms Heitler Department of Anesthesiology, College of Physicians and Surgeons of Columbia University Dr Whittington ; . Author Contributions: Dr Collins had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Collins, Kleber, Whittington, Heitler. Acquisition of data: Collins, Kleber, Whittington, Heitler. Analysis and interpretation of data: Collins, Kleber. Drafting of the manuscript: Collins, Kleber, Whittington, Heitler. Critical revision of the manuscript for important intellectual content: Collins, Kleber, Whittington. Obtained funding: Collins, Kleber. Administrative, technical, or material support: Collins, Kleber, Whittington, Heitler. Study supervision: Collins, Kleber, Whittington. Financial Disclosures: Dr Kleber has served as consultant for and has received an unrestricted grant from Reckitt Benckiser, the manufacturer of buprenorphine, for issues unrelated to this article. No other authors reported disclosures. Funding Support: This study was supported by grants DA-12644, DA-00317, and DA-14284 from the National Institute on Drug Abuse NIDA ; and grant MOIRR-00645 from the National Institutes of Health NIH ; . The present study was funded entirely by NIH grants. Role of the Sponsor: The study was reviewed by the Investigational Review Group at the National Institute on Drug Abuse when it recommended funding for this project. Beyond the review process, neither the NIH nor the NIDA had a role in the design, conduct, analysis, or writing of this study. Acknowledgment: We wish to thank the following individuals for their work in support of this research: Marty L. Hill, CRNA, and Jody Davis, CRNA, Department of Anesthesiology; Edward Nunes, MD, Division of Substance Abuse, and Dan Bloomfield, MD, Department of Medicine; and Maria Sullivan, MD, and Jay Mott, MD, Division of Substance Abuse, Department of Psychiatry, Columbia University Medical Center; Randi Adelman, RN; Research Assistants Chaim Kozlovsky and Michael Song; and Fatima Garawi, MA, for statistical support.

Then i started having female problems and then wondered if maybe it was my hormones that caused my hair to fall out. Her profile indicates she is on cyclosporine neoral ; , prednisone, asa, oscal d, norvasc, hctz and geodon.
Over 90% of surveyed homeless women reported severe physical and sexual assault during their lifetime Bassuk, 1996 43% were sexually molested as children Community Connections, 2002 ; . Homeless women are four times more likely than domiciled women to be raped. HIV infection is a risk factor for abuse, regardless of housing status. Of surveyed women with HIV, as many as 50% have suffered sexual abuse, and 60% have experienced domestic violence Song, 1999.
TABLE 2. Incidence of Sexual Side Effects in Placebo-Controlled Clinical Trials With EMSAM Adverse Event EMSAM Placebo IN MALES ONLY N 304 ; N 256 ; Abnormal Ejaculation 1.0% 0.0% Decreased Libido 0.7% 0.0% Impotence 0.7% 0.4% Anorgasmia 0.2% 0.0% IN FEMALES ONLY N 513 ; N 412 ; Decreased Libido 0.0% 0.2% There are no adequately designed studies examining sexual dysfunction with EMSAM treatment. Vital Sign Changes EMSAM and placebo groups were compared with respect to 1 ; mean change from baseline in vital signs pulse, systolic blood pressure, and diastolic blood pressure ; and 2 ; the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. In the pool of short-term, placebo-controlled major depressive disorder studies, 3.0% of EMSAM-treated patients and 1.5% of placebo-treated patients experienced a low systolic blood pressure, defined as a reading less than or equal to 90mmHg with a change from baseline of at least 20mmHg. In one study which utilized higher mean doses of EMSAM, 6.2% of EMSAM-treated patients and no placebo-treated patients experienced a low standing systolic blood pressure by these criteria. In the pool of short-term major depressive disorder trials, 9.8% of EMSAM-treated patients and 6.7% of placebo-treated patients experienced a notable orthostatic change in blood pressure, defined as a decrease of at least 10mmHg in mean blood pressure with postural change. Weight Changes In placebo-controlled studies 6-8 weeks ; , the incidence of patients who experienced 5% weight gain or weight loss is shown in Table 3. TABLE 3. Incidence of Weight Gain and Weight Loss in Placebo-Controlled Trials With EMSAM Weight Change EMSAM Placebo N 757 ; N 614 ; Gained 5% 2.1% 2.4% Lost 5% 5.0% 2.8% In these trials, the mean change in body weight among EMSAM-treated patients was -1.2 lbs compared to + 0.3 lbs in placebo-treated patients and paxil. A chest x-ray is frequently performed; it may point towards alternative diagnoses e, g.
CLINICAL PHARMACOLOGY Pharmacodynamics Selegiline the drug substance of EMSAM ; is an irreversible inhibitor of monoamine oxidase MAO ; , an intracellular enzyme associated with the outer membrane of mitochondria. MAO exists as two isoenzymes, referred to as MAO-A and MAO-B. Selegiline has a greater affinity for MAO-B, compared to MAO-A. However, at antidepressant doses, selegiline inhibits both isoenzymes see below ; . The mechanism of action of EMSAM as an antidepressant is not fully understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system CNS ; resulting from its inhibition of MAO activity. In an in vivo animal model used to test for antidepressant activity Forced Swim Test ; , selegiline administered by transdermal patch exhibited antidepressant properties only at doses that inhibited both MAO-A and cymbalta.

Sterling Retiree Rx Formulary Index diltiazem .20 diltiazem ext-rel.20 diltiazem inj .20 DIOVAN .18 DIOVAN HCT .18 DIPENTUM .34 diphenhydramine .40 diphenhydramine inj .40 diphenoxylate atropine .33 DIPHTHERIA AND TETANUS TOXOIDS ADSORBED.38 DIPHTHERIA, TETANUS TOXOIDS, ACELLULAR PERTUSSIS, HEPATITIS B RECOMBINANT ; , and POLIOVIRUS INACTIVATED ; VACCINE .38 DIPHTHERIA, TETANUS TOXOIDS, and ACELLULAR PERTUSSIS VACCINE .38 dipyridamole .36 disopyramide.18 disopyramide ext-rel.18 DOVONEX .43 doxazosin.18 doxepin .23 doxepin crm 5%.42 DOXIL .14 doxorubicin .14 doxycycline hyclate caps, tabs .10 doxycycline inj .10 DUONEB .39 econazole.42 EFFEXOR XR .23 EFUDEX crm 5% .42 ELAPRASE .30 ELIDEL .44 ELIXOPHYLLIN .41 ELLENCE .15 ELMIRON .36 ELSPAR.16 EMCYT . 14, 16 EMEND .33 EMSAM .23 EMTRIVA.11 enalapril .17 enalapril hydrochlorothiazide .18 ENBREL .37 ENTOCORT EC .34 EPIPEN .39 EPIPEN JR 39 - 51 -3T-Last Updated 10 30 2007 While all generics may not be listed, most generics are covered as Tier 1. 801.
Its proprietary formula is enriched with potent saw palmetto extract, keratin and vitamin e plus natural plant extracts and humectants to stimulate invigorate and nourish the scalp to get the most from your minoxidil-based re-growth program and seroquel. Emollient preparations such as balneum plus are of benefit where pruritis is associated with dry skin conditions such as dermatitis and eczema.

7-11. Initial emergency reduction of intracranial pressure is most rapidly accomplished by and sarafem. Wpi ; announced today that somerset pharmaceuticals, inc has received an approvable letter from the food and drug administration fda ; for emsam selegiline transdermal system ; , the company's transdermal therapy for which they are seeking an indication for the treatment of major depressive.
40413 2.52B ; Table G.23 Alcohol Use, Binge Alcohol Use, and Heavy Alcohol Use in the Past Month among Persons Aged 18 to 25, by Demographic Characteristics: Percentages, 2002 and 2003 TYPE OF ALCOHOL USE Any Alcohol Use Demographic Characteristic TOTAL GENDER Male Female HISPANIC ORIGIN AND RACE Not Hispanic or Latino White Black or African American American Indian or Alaska Native Native Hawaiian or Other Pacific Islander Asian Two or More Races Hispanic or Latino EDUCATION High School High School Graduate Some College College Graduate CURRENT EMPLOYMENT Full-Time Part-Time Unemployed Other1 2002 60.5 65.2 * 49.9 64.0 49.8 * 48.9 66.6 52.1 Binge Alcohol Use 2002 40.9 50.2 * 24.6 44.4 34.8 * 27.8 40.0 36.5 Heavy Alcohol Use 2002 14.9 21.1 * 7.0 19.5 9.1 * 7.8 16.6 10.8 and sinequan. According to their traditions, they came to nigeria by way of morocco sometime in the 16th century after the expulsion of the jews from spain in 149 their language is a mixture of moroccan arabic with yoruba, but with bits of aramaic, such as ima for mother.

In another trial, 322 patients meeting dsm-iv criteria for major depressive disorder who had responded during an initial 10-week open-label treatment phase for about 25 days, on average, to emsam 6 mg 24 hours were randomized either to continuation of emsam at the same dose n 159 ; or to placebo n 163 ; under double-blind conditions for observation of relapse and buspar.

The next step up in your supplementation program would include such things as the following: 1 - creatine 2 - glutamine 3 - a quality zma specifically forumlates zinc magnesium ; product sports supplements, like most things about fitness, has numerous opinions, and it's tough to know who to trust. EMSAM * is manufactured on behalf of Somerset by Mylan Technologies, Inc. in the U.S. through a third party. Somerset obtains finished goods from Mylan Technologies, Inc. The finished product is supplied to the Company by Somerset. Immunoscience ORENCIA Abatacept, a biological product, is a fusion protein with novel immunosuppressive activity targeted initially at adult patients with moderate to severe rheumatoid arthritis, who have had an inadequate response to certain currently available treatments. Abatacept was approved by the FDA in December 2005 and made commercially available in the U.S. in February 2006 and atarax. All other vegetables Processed cheeses, mozzarella, ricotta cheese, cottage cheese and yogurt As with other antidepressants, concomitant use of alcohol with EMSAM is not recommended. Bottled and canned beers and wines contain little or no tyramine. ; Brewer's yeast, baker's yeast, soy milk, commercial chain-restaurant pizzas prepared with cheeses low in tyramine. European Community Commission Decision 2002 657 EC allows the use of HPLC coupled with fluorescence detection [4] for substances in Group B of Annex I to Directive 96 23 EC. Quinolones and other veterinary drugs fall into Group B, where three identification points are required for confirmation by Selected Ion Monitoring SIM ; using mass spectrometry MS ; . With low resolution HPLC MS, one point can be earned for each ion detected, provided that the ion ratios meet relative intensity criteria. Additional requirements of Directive 2002 657 EC, based on spiking levels of 33 g carried out in this study, are as follows: The internal standard IS ; shall be added to the test portion at the beginning of the extraction procedure. In order to allow the use of data corrected for mean recovery, the range of recoveries allowed are 20% to + 10%. The reproducibility of coefficient variation CV ; % ; is expected to be about one-half to twothirds of the 100 g kg CV, which is 23%, at a concentration of half the permitted limit. For liquid chromatography mass spectrometry LC MS ; procedures, the minimum acceptable retention time RT ; for the analyte under examination is twice the RT corresponding to the void volume of the column. The ratio of the chromatographic RT of the analyte to that of the IS, that is, the relative RT of the analyte, shall correspond to that of the calibration solution at a tolerance of 2.5% for LC. The molecular ion shall preferably be one of the selected diagnostic ions. The maximum permitted tolerances for relative ion intensities shall meet the criteria in the Annex, in this case, either 25% or 30% ; , as reproduced in Table 6 and pamelor and Buy emsam. Physicians should gain control as quickly as possible, then step down to the least medication necessary to maintain control. A gradual stepwise reduction in treatment may be possible. However, if control is not maintained, physicians should consider stepping up medication. Metered dose inhalers MDIs ; can be used in infants and smaller children with appropriate spacer devices and masks. For pediatric patients who are uncooperative with inhaled medication delivery, compressed air-driven, wet nebulizers are available. 4. Follow-up Care.

Non-executive Chairman since February 2003 and Secretary since November 2006. President of Pear Tree Pharmaceuticals, Inc., Mr. Rocamboli was general counsel of Paramount BioCapital, Inc. and Paramount BioCapital Investments, LLC and served as deputy general counsel of those companies from September 1999 to August 2007. Former director of Adherex Technologies, Inc. Mr. Rocamboli also serves as a member of the board of directors of several privately held development stage biotechnology companies. Joined VioQuest in November 2007. Previously, he served as President and Chief Executive Officer at Cytogen Corporation since December 2002. Mr. Becker joined Cytogen in April 2001 and held positions of increasing responsibility, including Chief Executive Officer of AxCell Biosciences, a subsidiary of Cytogen focused on signal transduction pathways, and Vice President of Business Development and Industry Relations. Board of directors since 11 05. He currently serves as the Chairman of Kinex Pharmaceuticals, LLC, a position he has held since 12 03. Dr. Lau currently is a member of the board of directors of Chelsea Therapeutics International, Ltd. NASDAQ: CHTP ; , a publicly-held company. Prior to his position with Kinex Pharmaceuticals, Dr. Lau was an independent contractor from January 2003 until 12 03 and served in various capacities at Ribapharm Inc. from 8 2000 until 1 03, including Chairman, President and Chief Executive Officer. Previously he was the Senior Vice President and Head of Research and Development at ICN Pharmaceuticals and Senior Director of Antiviral Therapy at Schering-Plough Research Institute. He has published over 200 scientific papers and 40 reviews and editorials in leading academic journals and was elected as a Fellow, Royal College of Physicians in 2004 and holds an M.B.B.S. and M.D. from the University of Hong Kong and the degrees of M.R.C.P. and F.R.C.P. from the Royal College of Physicians. Founder and co-chairman of Actin Biomed, a New York based healthcare investment firm advancing the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin, Dr. Weiser was the Director of Research at Paramount BioCapital where he was responsible for the scientific, medical and financial evaluation of biomedical technologies and pharmaceutical products under consideration for development and glyset. Uitous intracellular enzyme. MAO exists as two isoenzymes, referred to as MAO-A and MAO-B. Selegiline shows greater affinity for MAO-B; however, as selegiline concentration increases, this selectivity is lost with resulting dose-related inhibition of MAO-A. Intestinal MAO is predominantly type A, while in the brain both isoenzymes exist. MAO plays a vital physiological role in terminating the biological activity of both endogenous and exogenous amines. In addition to their role in the catabolism of monoamines in the CNS, MAOs are also important in the catabolism of exogenous amines found in a variety of foods and drugs. MAO in the gastrointestinal tract primarily type A ; provides protection from exogenous amines with vasopressor actions, such as tyramine, which if absorbed intact can cause a hypertensive crisis, the so-called "cheese reaction." If a large amount of tyramine is absorbed systemically, it is taken up by adrenergic neurons and causes norepinephrine release from neuronal storage sites with resultant elevation of blood pressure. While most foods contain negligible amounts or no tyramine, a few food products see WARNINGS ; may contain large amounts of tyramine that represent a potential risk for patients with significant inhibition of intestinal MAO-A resulting from administration of MAOIs. Tyramine-containing nutritional supplements should be avoided by patients taking EMSAM selegiline transdermal system ; . Animal studies have indicated the transdermal administration of selegiline via EMSAM 6 mg 24 hours allows for critical levels of MAO inhibition to be achieved in the brain while avoiding levels of gastrointestinal inhibition. To further define the risk of hypertensive crises with use of EMSAM, several Phase I tyramine challenge studies were conducted both with and without food. Fourteen tyramine challenge studies including 214 healthy subjects age range 18 - 65; 31 subjects 50 years of age ; were conducted to determine the pressor effects of oral tyramine with concurrent EMSAM treatment 6 mg 24 hours - 12 mg 24 hours ; , measured as the dose of tyramine required to raise systolic blood pressure by 30 mmHg TYR30 ; . Studies were conducted with and without concomitant administration of food. Studies conducted with food are most relevant to clinical practice since tyramine typically will be consumed in food. A high-tyramine meal is considered to contain up to 40 mg of tyramine. One study using a crossover design in 13 subjects investigated tyramine pressor doses TYR30 ; after administration of EMSAM 6 mg 24 hours and oral selegiline 5 mg twice daily ; for 9 days. Mean pressor doses TYR30 ; of tyramine capsules administered without food were 338 mg and 385 mg in subjects treated with EMSAM and oral selegiline, respectively. Another study using a crossover design in 10 subjects investigated tyramine pressor doses after administration of EMSAM 6 mg 24 hours or tranylcypromine 30 mg day for 10 days. Mean pressor doses TYR30 ; of tyramine capsules administered without food were 270 mg in subjects treated with EMSAM 6 mg 24 hours and 10 mg in subjects treated with tranylcypromine. In a third crossover study, tyramine without food was administered to 12 subjects. The mean tyramine pressor doses TYR30 ; after administration of EMSAM 6 mg 24 hours for 9 and 33 days were 292 mg and 204 mg, respectively. The lowest pressor dose was 50 mg in one subject in the 33-day group. Tyramine pressor doses were also studied in 11 subjects after extended treatment with EMSAM 12 mg 24 hours. At 30, 60, and 90 days, the mean pressor doses TYR30 ; of tyramine administered without food were 95 mg, 72 mg, and 88 mg, respectively. The lowest pressor dose without food was 25 mg in 3 subjects at day 30 while on EMSAM 12 mg 24 hours. Eight subjects from this study, with a mean tyramine pressor dose of 64 mg at 90 days, were subsequently administered tyramine with food, resulting in a mean pressor dose of 172 mg 2.7 times the mean pressor dose observed without food, p 0.003 ; . With the exception of one study N 153 ; , the Phase III clinical development program was conducted without requiring a modified diet N 2553, 1606 at 6 mg 24 hours, and 947 at 9 mg 24 hours or 12 mg 24 hours ; . No hypertensive crises were reported in any patient receiving EMSAM. In its entirety, the data for EMSAM 6 mg 24 hours support the recommendation that a modified diet is not required at this dose. Due to the more limited data available for EMSAM 9 mg 24 hours and 12 mg 24 hours, patients receiving these doses should follow Dietary Modifications Required for Patients Taking EMSAM 9 mg 24 hours and 12 mg 24 hours. See WARNINGS. ; Warfarin Warfarin is a substrate for CYP2C9 and CYP3A4 metabolism pathways. In healthy volunteers titrated with Coumadin warfarin sodium ; to clinical levels of anticoagulation INR of 1.5 to 2 ; , co-administration with EMSAM 6 mg 24 hours for 7 days did not affect the pharmacokinetics of the individual warfarin enantiomers. EMSAM did not alter the clinical pharmacodynamic effects of warfarin as measured by INR, Factor VII or Factor X levels. Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In an oral carcinogenicity study in rats, selegiline given in the diet for 104 weeks was not carcinogenic up to the highest evaluable dose tested 3.5 mg kg day, which is 3 times the oral maximum recommended human dose on a mg m2 basis ; . Carcinogenicity studies have not been conducted with transdermal administration of selegiline. Mutagenesis Selegiline induced mutations and chromosomal damage when tested in the in vitro mouse lymphoma assay with and without metabolic activation. Selegiline was negative in the Ames assay, the in vitro mammalian chromosome aberration assay in human lymphocytes, and the in vivo oral mouse micronucleus assay. Impairment of Fertility A mating and fertility study was conducted in male and female rats at transdermal doses of 10, 30, and 75 mg kg day of selegiline 8, 24, and 60 times the maximum recommended human dose of EMSAM [12 mg 24 hours] on a mg m2 basis ; . Slight decreases in sperm concentration and total sperm count were observed at the high dose; however, no significant adverse effects on fertility or reproductive performance were observed. Teratogenic Effects - Pregnancy Category C In an embryofetal development study in rats, dams were treated with transdermal selegiline during the period of organogenesis at doses of 10, 30, and 75 mg kg day 8, 24, and 60 times the maximum recommended human dose [MRHD] of EMSAM [12 mg 24 hours] on a mg m2 basis ; . At the highest dose there was a decrease in fetal weight and slight increases in malformations, delayed ossification also seen at the mid dose ; , and embryofetal post-implantation lethality. Concentrations of selegiline and its metabolites in fetal plasma were generally similar to those in maternal plasma. In an oral embryofetal development study in rats, a decrease in fetal weight occurred at the highest dose tested 36 mg kg; no-effect dose 12 mg kg no increase in malformations was seen. In an embryofetal development study in rabbits, dams were treated with transdermal selegiline during the period of organogenesis at doses of 2.5, 10, and 40 mg kg day 4, 16, and 64 times the MRHD on a mg m2 basis ; . A slight increase in visceral malformations was seen at the high dose. In an oral embryofetal development study in rabbits, increases in total resorptions and post-implantation loss, and a decrease in the number of live fetuses per dam, occurred at the highest dose tested 50 mg kg; no-effect dose 25 mg kg ; . In a prenatal and postnatal development study in rats, dams were treated with transdermal selegiline at doses of 10, 30, and 75 mg kg day 8, 24, and 60 times the MRHD on a mg m2 basis ; on days 6 - 21 of gestation and days 1 - 21 of the lactation period. An increase in post-implantation loss was seen at the mid and high doses, and an increase in stillborn pups was seen at the high dose. Decreases in pup weight throughout lactation and post-weaning periods ; and survival throughout lactation period ; , retarded pup physical development, and pup epididymal and testicular hypoplasia, were seen at the mid and high doses. Retarded neurobehavioral and sexual development was seen at all doses. Adverse effects on pup reproductive performance, as evidenced by decreases in implantations and litter size, were seen at the high dose. These findings suggest persistent effects on the offspring of treated dams. A no-effect dose was not established for developmental toxicity. In this study, concentrations of selegiline and its metabolites in milk were ~ 15 and 5 times, respectively, the concentrations in plasma, indicating that the pups were directly dosed during the lactation period. There are no adequate and well-controlled studies in pregnant women. EMSAM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Labor and Delivery The effect of EMSAM on labor and delivery in humans is unknown. Nursing Mothers In a prenatal and postnatal study of transdermal selegiline in rats, selegiline and metabolites were excreted into the milk of lactating rats. The levels of selegiline and metabolites in milk were approximately 15 and 5 times, respectively, steady-state levels of selegiline and metabolites in maternal plasma. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised administering EMSAM to a nursing mother. Pediatric Use Safety and effectiveness in the pediatric population have not been established see BOX WARNING and WARNINGS, Clinical Worsening and Suicide Risk.
If you get shots, make sure that you tell the nurse or doctor about any reactions to the shots, any current illnesses and any medications that you're taking.
Both cause a degree of numbness in the extremeties and some edema again, maybe causing weight gain. Wish that had come up earlier actually in our discussions. Any further questions? Okay. Let me reread it. If the EMSAM 20 mg patch formulation could be considered reasonably safe--the question is are. Liquid-liquid extraction of drugs and other lipophilic poisons from the specimen into an appropriate, water-immiscible, organic solvent, usually at a controlled pH, is widely used in analytical toxicology. Solvent extraction removes water and dissolved interfering compounds, and reduction in volume by evaporation ; of the extract before analysis provides a simple means of concentrating the compounds of interest and thus enhancing sensitivity. Some form of mechanical mixing of the aqueous and organic phases is normally necessary. Of the methods available, vortex-mixing is the quickest and the most efficient for relatively small volumes. Rotary mixers capable of accepting tubes of up to ml in volume are valuable for performing relatively large volume extracts of plasma serum, urine, or stomach contents, and serve to minimize the risk of emulsion formation. Centrifugation in a bench-top centrifuge, again capable of accepting test-tubes of up to 30 ml in volume and attaining speeds of 2000-3000 rev min, is normally effective in separating the phases so that the organic extract can be removed. Ideally, the centrifuge should have a sealed motor unit which is flashproof ; and tubes should be sealed to minimize both the risk of explosion from ignition of solvent vapour and the risks associated with centrifugation of infective specimens. Finally, filtration of the organic extract through silicone-treated phase-separating paper prevents contamination of the extract with small amounts of aqueous phase. Commercial prebuffered extraction tubes so-called solid-phase extraction ; are now widely used for liquid-liquid extraction, especially in preparing urine extracts for drug screening see section 5.2.3 ; . Such tubes have the advantage that a wide range of basic compounds, including morphine, and weak acids, such as barbiturates, can be extracted in a single step. However, they are relatively expensive and cannot be reused. 4.3.3 Microdiffusion and buy geodon.

Buy cheap Emsam